Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$20.93 - $35.1 $892,601 - $1.5 Million
-42,647 Closed
0 $0
Q3 2019

Oct 18, 2019

SELL
$22.08 - $47.08 $126,297 - $269,297
-5,720 Reduced 11.83%
42,647 $1.22 Million
Q2 2019

Aug 01, 2019

BUY
$22.67 - $35.0 $45,271 - $69,895
1,997 Added 4.31%
48,367 $1.34 Million
Q1 2019

May 03, 2019

BUY
$26.93 - $34.7 $113,132 - $145,774
4,201 Added 9.96%
46,370 $1.54 Million
Q4 2018

Feb 11, 2019

SELL
$27.23 - $45.56 $92,282 - $154,402
-3,389 Reduced 7.44%
42,169 $1.23 Million
Q3 2018

Nov 14, 2018

BUY
$37.57 - $50.34 $1.71 Million - $2.29 Million
45,558 New
45,558 $2.1 Million
Q3 2017

Nov 08, 2017

SELL
$24.01 - $36.2 $7.38 Million - $11.1 Million
-307,413 Closed
0 $0
Q2 2017

Aug 10, 2017

BUY
N/A
307,413
307,413 $7.94 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.11B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Stephens Inc Portfolio

Follow Stephens Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.